Carsten Hamann, MD
Dermatology · Phoenix, AZNPI 1538546957
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $252,962 of the $364,367 with a category attached, or 69.4%. 38 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 43.9% of the total. 2025 is the largest year on record at $228,357, more than ten times the $279 reported in 2021. Among dermatology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 633 payments — averaging $575.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$160K
- Sanofi$128K
- Pfizer$49K
- Galderma Laboratories, L.p.$10K
- LEO Pharma Inc.$4K
- LEO Pharma AS$3K
- plus $10K from 32 others
Across 1 payment — averaging $1,338,598 each. An ownership or investment interest held by the physician or an immediate family member.
- Allerderm Laboratories$1.3M
What the payments were for
- Consulting fees$75,24521%
- Speaking & faculty fees$252,96269%
- Travel & lodging$18,9405%
- Food & beverage$16,6435%
- Education$5780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$364,367 in reported general payments places this provider in the 95th percentile of 305 dermatology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 129 | $6,204 |
| Fluorouracil | 61 | $4,369 |
| Triamcinolone Acetonide | 215 | $2,527 |
| Ketoconazole | 102 | $1,672 |
| Metronidazole | 20 | $842 |
| Doxycycline Hyclate | 25 | $521 |
| Doxycycline Monohydrate | 16 | $447 |
| Clindamycin Phosphate | 13 | $413 |
| Imiquimod | 11 | $294 |
| Mupirocin | 16 | $110 |
| Prednisone | 12 | $78 |
| Hydrocortisone | 14 | $63 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Phoenix
- Lindsay AckermanPhoenix$1.6M
- Nathalie ZeitouniPhoenix$584K
- Michael CrandallPhoenix$153K
- Sadra JazayeriPhoenix$115K
- Cynthia PricePhoenix$76K
- William KoPhoenix$66K
- Dathan HamannPhoenix$56K
- Peter SigalPhoenix$30K
- Xuan NguyenPhoenix$19K
- Christina HarviewPhoenix$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.